Innocan Pharma Corp (INNO.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 9 | 9 | 7 | 13 | 4 |
| Accounts receivable | -21 | -83 | -87 | 38 | 72 |
| Accounts payable and accrued liabilities | 156 | -112 | 194 | -44 | -109 |
| Other Working Capital | -112 | -366 | -22 | -226 | -329 |
| Other Operating Activity | -750 | -161 | -1,254 | -1,145 | -997 |
| Operating Cash Flow | $-718 | $-713 | $-1,162 | $-1,364 | $-1,359 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1 | -9 | -27 | -11 | -3 |
| Other Investing Activity | -31 | 0 | -7 | -5 | 0 |
| Investing Cash Flow | $-32 | $-9 | $-34 | $-16 | $-3 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -5 | -6 | -6 | -2 | 4 |
| Common Stock Issued | 762 | 0 | 209 | 0 | 0 |
| Other Financing Activity | 691 | 0 | 154 | 0 | 111 |
| Financing Cash Flow | $1,448 | $-6 | $357 | $-2 | $115 |
| Exchange Rate Effect | -47 | 12 | -19 | -87 | -63 |
| Beginning Cash Position | 3,373 | 4,089 | 4,947 | 6,416 | 7,726 |
| End Cash Position | 4,024 | 3,373 | 4,089 | 4,947 | 6,416 |
| Net Cash Flow | $698 | $-728 | $-839 | $-1,382 | $-1,247 |
| Free Cash Flow | |||||
| Operating Cash Flow | -718 | -713 | -1,162 | -1,364 | -1,359 |
| Capital Expenditure | -1 | -9 | -27 | -11 | -3 |
| Free Cash Flow | -719 | -722 | -1,189 | -1,375 | -1,362 |